Pharmacist Payment Reform Is Accelerating — A 2026 State-by-State Update
A summary of "State of the Union 2026: State-Level Updates and National Trends in Pharmacist Payment Reform" by the Advancing Pharmacist Payment Parity Workgroup of the American College of Clinical Pharmacy (ACCP)
Pharmacists' clinical roles are expanding across the country — but can they get paid for the services they provide? A 2026 update from the Advancing Pharmacist Payment Parity Workgroup, a national collaborative of more than 50 pharmacy faculty, clinicians, and policy experts, offers the most current picture of where state-level reimbursement stands and how fast the landscape is changing.
The big numbers
The workgroup reviewed legislative, regulatory, and Medicaid policy changes enacted between April 2024 and April 2026. They found that 43 states (86%) now have some mechanism that enables payment for pharmacist-delivered clinical services. Seventeen states have enacted broad commercial coverage requirements — meaning insurers must reimburse pharmacists for services within their scope of practice when those services would be covered if delivered by another provider. On the Medicaid side, 22 states have established broad coverage, and another 19 cover a narrower set of services.
Since the workgroup's 2024 report, substantial reforms occurred in 16 states: Alaska, Connecticut, Delaware, Hawaii, Idaho, Illinois, Indiana, Kansas, Kentucky, Louisiana, Maine, Michigan, Minnesota, North Carolina, Oregon, and Utah. Changes ranged from new Medicaid provider enrollment pathways and test-and-treat authority to full payment parity mandates spanning both commercial and Medicaid payers.
Key trends
The article identifies several patterns shaping the current wave of reform. States are increasingly tying new scope-of-practice authority directly to reimbursement eligibility, rather than expanding scope and hoping payment follows. Medicaid programs continue to serve as early adopters of pharmacist billing pathways. And many states are pursuing a phased strategy — mandating coverage for specific services like contraceptive prescribing or HIV PrEP first, then building toward broader nondiscrimination statutes.
At the same time, the authors flag persistent barriers: ERISA limits states' ability to regulate self-funded employer plans, fee schedule parity varies widely (from full parity to 75% of physician rates), and practice setting restrictions remain common.
Why this matters for PharmacyBridge readers
PharmacyBridge tracks pharmacist authority to prescribe, administer, and provide buprenorphine-related care across 52 U.S. jurisdictions. This article reinforces one of the project's core tenets: authority without reimbursement is unsustainable. A pharmacist may have legal authority to provide or manage buprenorphine under a collaborative practice agreement, but if no payer will reimburse the service, the service will not be widely implemented, and therefore the public health benefits of increased OUD treatment access will not be realized.
The workgroup's conclusion — that sustainable integration of pharmacist services requires alignment between scope of practice, payment infrastructure, and implementation capacity — maps directly onto the gaps PharmacyBridge documents in OUD care. As more states build reimbursement pathways, the question for buprenorphine access becomes not just can pharmacists provide this care, but will they be paid for it.
Read the full article: State of the Union 2026 — Journal of the American College of Clinical Pharmacy, 2026;9:e70214.
